Corporate Preclinical R&D
Gino Villetti has not added Biography.
If you are Gino Villetti and would like to personalize this page please email our Author Liaison for assistance.
Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist.
Neuroreport Nov, 2002 | Pubmed ID: 12438928
The protective effect of ganstigmine against amyloid beta 25-35 neurotoxicity on chicken cortical neurons is independent from the cholinesterase inhibition.
Neuroscience letters May, 2003 | Pubmed ID: 12697278
Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain.
The Journal of pharmacology and experimental therapeutics Aug, 2003 | Pubmed ID: 12750440
Mechanisms of action of CHF3381 in the forebrain.
British journal of pharmacology Aug, 2003 | Pubmed ID: 12890713
Ganstigmine and donepezil improve neurodegeneration in AD11 antinerve growth factor transgenic mice.
American journal of Alzheimer's disease and other dementias May-Jun, 2004 | Pubmed ID: 15214201
High throughput screening of beta-amyloid secretion inhibitors using homogenous time-resolved fluorescence.
Combinatorial chemistry & high throughput screening Dec, 2004 | Pubmed ID: 15578936
CHF3381, a novel antinociceptive agent, attenuates capsaicin-induced pain in rats.
European journal of pharmacology Sep, 2005 | Pubmed ID: 16125167
Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.
Journal of medicinal chemistry Sep, 2005 | Pubmed ID: 16134939
Synthesis and anticonvulsant activity of a class of 2-amino 3-hydroxypropanamide and 2-aminoacetamide derivatives.
Bioorganic & medicinal chemistry May, 2006 | Pubmed ID: 16460950
Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea-pig and human airways.
British journal of pharmacology Jun, 2006 | Pubmed ID: 16565730
Structural determinants of Torpedo californica acetylcholinesterase inhibition by the novel and orally active carbamate based anti-alzheimer drug ganstigmine (CHF-2819).
Journal of medicinal chemistry Aug, 2006 | Pubmed ID: 16913695
Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide.
The Journal of biological chemistry Apr, 2007 | Pubmed ID: 17267402
In vitro and in vivo profiling of CHF5022 and CHF5074 Two beta-amyloid1-42 lowering agents.
Pharmacological research Apr, 2007 | Pubmed ID: 17292621
Formoterol and beclomethasone dipropionate interact positively in antagonising bronchoconstriction and inflammation in the lung.
Pharmacological research May, 2007 | Pubmed ID: 17336541
Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M3 selective antagonists (Part 1).
Journal of medicinal chemistry Apr, 2007 | Pubmed ID: 17352462
Discovery of diaryl imidazolidin-2-one derivatives, a novel class of muscarinic M3 selective antagonists (Part 2).
Journal of medicinal chemistry Apr, 2007 | Pubmed ID: 17352463
1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.
The Journal of pharmacology and experimental therapeutics Dec, 2007 | Pubmed ID: 17895400
CHF5074, a novel gamma-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease.
Journal of Alzheimer's disease : JAD , 2010 | Pubmed ID: 20164581
Evaluation of lung inflammation induced by intratracheal administration of LPS in mice: comparison between MRI and histology.
Magma (New York, N.Y.) Apr, 2010 | Pubmed ID: 20386954
Acetaminophen, via its reactive metabolite N-acetyl-p-benzo-quinoneimine and transient receptor potential ankyrin-1 stimulation, causes neurogenic inflammation in the airways and other tissues in rodents.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology Dec, 2010 | Pubmed ID: 20720158
The γ-secretase modulator CHF5074 restores memory and hippocampal synaptic plasticity in plaque-free Tg2576 mice.
Journal of Alzheimer's disease : JAD , 2011 | Pubmed ID: 21321397
Unbalanced oxidant-induced DNA damage and repair in COPD: a link towards lung cancer.
Thorax Jun, 2011 | Pubmed ID: 21460372
Therapeutic effect of CHF5074, a new γ-secretase modulator, in a mouse model of scrapie.
Prion Jan-Mar, 2012 | Pubmed ID: 22453180
In vivo imaging of transiently transgenized mice with a bovine interleukin 8 (CXCL8) promoter/luciferase reporter construct.
PloS one , 2012 | Pubmed ID: 22761878
Receptor for advanced glycation end products contributes to postnatal pulmonary development and adult lung maintenance program in mice.
American journal of respiratory cell and molecular biology Feb, 2013 | Pubmed ID: 23144333
Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice.
BMC neuroscience Apr, 2013 | Pubmed ID: 23560952
Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases.
Journal of medicinal chemistry Feb, 2014 | Pubmed ID: 24400806
Enlightened Mannhemia haemolytica lung inflammation in bovinized mice.
Veterinary research Jan, 2014 | Pubmed ID: 24460618
Azithromycin inhibits nuclear factor-κB activation during lung inflammation: an in vivo imaging study.
Pharmacology research & perspectives Oct, 2014 | Pubmed ID: 25505605
CHF6001 II: a novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration--in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window.
The Journal of pharmacology and experimental therapeutics Mar, 2015 | Pubmed ID: 25576073
CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration.
The Journal of pharmacology and experimental therapeutics Mar, 2015 | Pubmed ID: 25576075
In vivo imaging of the lung inflammatory response to Pseudomonas aeruginosa and its modulation by azithromycin.
Journal of translational medicine Aug, 2015 | Pubmed ID: 26239109
Monitoring inflammation and airway remodeling by fluorescence molecular tomography in a chronic asthma model.
Journal of translational medicine Oct, 2015 | Pubmed ID: 26496719
Assessment of asthmatic inflammation using hybrid fluorescence molecular tomography-x-ray computed tomography.
Journal of biomedical optics Jan, 2016 | Pubmed ID: 26803669
Anti-inflammatory effects of the novel inhaled phosphodiesterase type 4 inhibitor CHF6001 on virus-inducible cytokines.
Pharmacology research & perspectives Feb, 2016 | Pubmed ID: 26977295
In vivo monitoring of lung inflammation in CFTR-deficient mice.
Journal of translational medicine Jul, 2016 | Pubmed ID: 27468800
Physiological, Biochemical, and Biophysical Characterization of the Lung-Lavaged Spontaneously-Breathing Rabbit as a Model for Respiratory Distress Syndrome.
PloS one , 2017 | Pubmed ID: 28060859
Heterologous Matrix Metalloproteinase Gene Promoter Activity Allows In Vivo Real-time Imaging of Bleomycin-Induced Lung Fibrosis in Transiently Transgenized Mice.
Frontiers in immunology , 2017 | Pubmed ID: 28298912
Longitudinal assessment of bleomycin-induced lung fibrosis by Micro-CT correlates with histological evaluation in mice.
Multidisciplinary respiratory medicine , 2017 | Pubmed ID: 28400960
The PDE4 inhibitor CHF-6001 and LAMAs inhibit bronchoconstriction-induced remodelling in lung slices.
American journal of physiology. Lung cellular and molecular physiology Jun, 2017 | Pubmed ID: 28596292
Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases.
Journal of medicinal chemistry Dec, 2017 | Pubmed ID: 29200281
Gabriella Bergamini*,1,
Fabio Stellari*,2,
Angela Sandri*,3,
Maria M. Lleo3,
Gaetano Donofrio4,
Francesca Ruscitti5,2,
Federico Boschi6,
Andrea Sbarbati7,
Gino Villetti2,
Paola Melotti8,
Claudio Sorio1
1Department of Medicine, General Pathology Division, Cystic Fibrosis Translational Research Laboratory "D. Lissandrini", University of Verona,
2Corporate Preclinical R&D, Chiesi Farmaceutici S.p.A.,
3Department of Diagnostic and Public Health, Microbiology Division, University of Verona,
4Dipartimento di Scienze Medico-Veterinarie, University of Parma,
5Department of Biomedical Biotechnological and Translational Sciences, University of Parma,
6Department of Computer Science, University of Verona,
7Department of Neurological, Biomedical and Movement Sciences, University of Verona,
8Cystic Fibrosis Regional Center (CFC), AOUI Verona
JoVE 소개
Copyright © 2024 MyJoVE Corporation. 판권 소유